RNA interference (RNAi) as a form of antisense therapy
is also described.
Oncotelic is developing a unique TGF-b antisense therapy
which has demonstrated the ability to break immune tolerance in mid-stage clinical trials for the treatment of glioblastoma and pancreatic cancer.
IONIS-TMPRSS6-LRx, an antisense therapy
in development for people suffering with beta-thalassemia and other potential indications, is one of several of Ionis' advanced LIgand Conjugated Antisense, or LICA, drugs to demonstrate potent target reduction and a favorable safety and tolerability profile in humans.
targeting apolipoprotein(a); a randomized double blind, placebo controlled phase 1 study.
Then, several chapters address how natural compounds can be used in biosynthetic engineering, antisense therapy
, and motif hybridization.
"The issuance of this patent expands our intellectual property estate for treating clusterin-expressing cancers using antisense therapy
and provides us with a broad patent that applies well beyond prostate cancer," said Scott Cormack, President and CEO of OncoGenex.
Consisting of 20 papers by an international group of academics and those in industry, the publication covers research on new chemistries, antisense therapy
, the biology and applications of small interfering RNAs, aptamer technology, oligonucleotide-directed alternative splicing, triplex- forming oligonucleotides, immunostimulatory biology and applications, combating HIV infection, and delivery strategies.
The publication reports that in patients evaluable for prostate-specific antigen (PSA) there were seven PSA responses (reductions of greater than 50%), seven disease stabilizations and one disease progression on this regimen of antisense therapy
targeting the R2 component of ribonucleotide reductase combined with docetaxel and prednisone.
Promising investigational biologic therapies, many of them now in early clinical trials, include vaccines, monoclonal antibodies, dendritic cells, signal transduction inhibitors, telomerase inhibitors, apoptosis inducers, angiogenesis inhibitors, and antisense therapy
Promising investigational biologic therapies, many now in early clinical trials, include vaccines, monoclonal antibodies, dendritic cells, signal transduction inhibitors, telomerase inhibitors, apoptosis inducers, angiogenesis inhibitors, and antisense therapy
Scientists say a new technique called "antisense therapy
" has been successfully used to treat a version of the disease in mice.
The international patents were published under the auspices of the World Intellectual Property Organization according to the Patent Cooperation Treaty (PCT), expanding the CytoGenix patent portfolio of antisense therapy